Skip to main content

Table 4 Grade 3/4 non-serious adverse events

From: A phase I study of ridaforolimus in adult Chinese patients with advanced solid tumors

Grade 3 Number of patients and percentage
Anaemia 2/15, 13.3%
Stomatitis 2/15, 13.3%
Fatigue 2/15, 13.3%
Platelet count decrease 1/15, 6.7%
Constipation 1/15, 6.7%
Gamma-glutamyltransferase increase 1/15, 6.7%
Proteinuria 1/15, 6.7%
Grade 4  
Anaemia 1/15, 6.7%
Platelet count decrease 1/15, 6.7%